IPA is pleased to announce that Dr Rao Vadlamudi, Immediate Past President of the Indian Pharmaceutical Association (IPA), has been re-elected as the President of the Commonwealth Pharmacists Association (CPA) for the year 2020-22. IPA has forwarded the nomination of Dr Rao Vadlamudi for the CPA President position and the election results were announced on 26th September 2020 during the annual assembly of CPA. Dr Rao Vadlamudi is the second Indian professional to be elected as CPA President for the term 2017–19 and now re-elected for the term of 2020-22.

The first CPA President from India was late Dr J. N. Banerjee during the period 1982-1987. The CPA is an organization of national pharmaceutical bodies of the Commonwealth countries and individual members with an objective to empowering pharmacists to improve health and well-being throughout the Commonwealth, thereby adding quality to the range of services offered by the pharmacists, and its headquarter is based at London, United Kingdom.

Dr Rao Vadlamudi was the President of IPA, India for the period 2014-18. During this period, he ably led the Association in organizing hugely successful international and national events including the 61st International Pharmaceutical Students’ Federation (IPSF) World Congress in 2015. During this period, he also initiated advocacy with the Indian government, pushing forth policy inputs and documents, furthering the cause of pharmacists and the pharmacy profession in the country. Under his tutelage, in December 2016, IPA went on to organize another hugely successful mega event – the Indian Pharmaceutical Congress (IPC) that witnessed participation of over 10,000 national and international delegates from various facets of the profession. His active partnering with leaders of international organizations like FIP, FAPA and WHPA has helped him espouse some of the raging health care issues including tackling Antimicrobial Resistance and Campaign against Drug Counterfeiting globally. An academician par excellence and an eminent scientist with an impeccable knowledge base, Dr Rao Vadlamudi has also had an illustrious stint with the industry where he has led teams of scientists in cutting-edge drug discovery programs in companies like Hoechst India Ltd (Sanofi) and Nektar Therapeutics India Limited.

IPA feels proud of this rare honour and congratulates Dr Rao Vadlamudi for this great achievement.